The Insight Partners published latest research study on “Human Microbiome Market to 2028 – Global Analysis and Forecast – by Product, Application, Disease, and Geography,” the market is projected to reach US$ 2921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021–2028.
The market growth is attributed to increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing technological advancements in metagenomics and next-generation sequencing. However, the enforcement of strict government guidelines and lack of knowledge about detailed examination hinder the human microbiome market growth.
Download PDF Brochure: https://www.theinsightpartners.com/sample/TIPBT00002233/
The human microbiota consists of the trillions of symbiotic microbial cells harbored by each person, mainly bacteria in the gut, the human microbiome consists of the genes these cells harbor. The microbes including bacteria, fungi and viruses are the disease-causing microbes that accumulate over time and changing their gene activity & metabolic processes and resulting in an abnormal immune response against the substances and tissues that normally present in the human body. Microbiome projects across the globe have been launched with the aim to understand the roles that these symbionts play and their impacts on human health.
Patient Interactions with Lab Organizations Fuel Human Microbiome Market Growth
As the human microbiome industry is growing in the coming years and the number of applications expands, new markets are emerging that use that human microbiome in different ways. Emerging markets in developing countries hold significant opportunities for the business expansion of major players. Most of the market players focusing on the emerging markets in Asia Pacific due to an increase in the prevalence of various diseases in the region. In June 2017, the Indian Human Microbiome Project was launched in the northeastern region for supporting the discovery of new drugs and pharmaceuticals. The project also provides new understanding on the mutual relationship between humans and associated microbial flora. Due to existing rates of currency exchange and several other factors, treatments in India are cheaper than other foreign countries.
Browse key market insights spread across 188 pages with 84 list of tables & 78 list of figures from the report, “Human Microbiome Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product (Probiotics, Foods, Prebiotics, Medical Foods, Diagnostic Device, Drugs and Supplements), Disease (Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders, and Others) and Application (Therapeutics and Diagnostics) and Geography” in detail along with the table of contents: https://www.theinsightpartners.com/reports/human-microbiome-market
Human Microbiome Market: Competition Landscape and Key Developments
Rebiotix Inc., Yakult Honsha Co., Ltd., Synthetic Biologics, Inc., DuPont, MaaT Pharma, Eligo Bioscience, Merck & Co., Inc, AOBiome LLC, Kaleido; and Seres Therapeutics are among the key companies operating in the human microbiome market. Leading players are focusing on the launch of new products, expansion and diversification of their market presence, and acquisition of other companies for tapping prevailing business opportunities.
In July 2021, Seres Therapeutics, Inc. and Nestlé Health Science entered into commercialization license agreement to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the US and Canada.
In June 2021, MaaT Pharma received Data Safety and Monitoring Board (DSMB) approval to proceed with the phase 1b trial cohort study for testing the capsule formulation of microbiome ecosystem therapy.
Speak to Research Expert: https://www.theinsightpartners.com/speak-to-analyst/TIPBT00002233
North America is expected to hold the largest share of the human microbiome market in 2021. Its dominance in the global market is ascribed to the high concentration of market players in the US and Canada, surge in the number of conferences and meetings, and rising prevalence of chronic diseases. In February 2018, the 3rd Annual North America Microbiome Congress was held in San Diego by Kisaco Research, with a major focus on the gut, lung, oral, skin, and vaginal microbiome niches; it provided latest insights on microbiome research, clinical trials, and collaborative partnerships.
Human Microbiome Market: Segmental Overview
Based on application, the human microbiome market is segmented into segmented into diagnostics and therapeutics. The therapeutics segment is expected to hold a larger share of the market in 2021 and is estimated to register the highest CAGR during the forecast period. Surge in digestive issues, increase in drug-related side-effects, and development of therapies for chronic diseases such as cancer are among the factors that are likely to propel the growth of the market for the therapeutics segment during the forecast period.
Purchase Premium Copy of Human Microbiome Market Growth Report (2021-2028) at: https://www.theinsightpartners.com/buy/TIPBT00002233/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/human-microbiome-market